Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 56

1.

Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.

Santos FP, Kantarjian H, McConkey D, O'Brien S, Faderl S, Borthakur G, Ferrajoli A, Wright J, Cortes J.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):355-60. doi: 10.1016/j.clml.2011.06.004.

PMID:
21816374
[PubMed - indexed for MEDLINE]
2.

Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients.

Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, Nicholson M, Wahlberg J, Wissing KM, Abrams K, Witte S, Woodle ES.

Am J Transplant. 2011 Jul;11(7):1444-55. doi: 10.1111/j.1600-6143.2011.03538.x. Epub 2011 May 12.

PMID:
21564523
[PubMed - indexed for MEDLINE]
Free Article
3.

Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis.

Diaz T, Navarro A, Ferrer G, Gel B, Gaya A, Artells R, Bellosillo B, Garcia-Garcia M, Serrano S, Martínez A, Monzo M.

PLoS One. 2011 Apr 20;6(4):e18856. doi: 10.1371/journal.pone.0018856.

PMID:
21533094
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.

Shide K, Kameda T, Markovtsov V, Shimoda HK, Tonkin E, Fang S, Liu C, Gelman M, Lang W, Romero J, McLaughlin J, Bhamidipati S, Clough J, Low C, Reitsma A, Siu S, Pine P, Park G, Torneros A, Duan M, Singh R, Payan DG, Matsunaga T, Hitoshi Y, Shimoda K.

Blood. 2011 Jun 23;117(25):6866-75. doi: 10.1182/blood-2010-01-262535. Epub 2011 Apr 29.

PMID:
21531978
[PubMed - indexed for MEDLINE]
Free Article
5.

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.

Stump KL, Lu LD, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM.

Arthritis Res Ther. 2011 Apr 21;13(2):R68. doi: 10.1186/ar3329.

PMID:
21510883
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ.

J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7.

PMID:
21383241
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S.

Nat Rev Drug Discov. 2011 Feb;10(2):127-40. doi: 10.1038/nrd3264. Review. Erratum in: Nat Rev Drug Discov. 2011 Apr;10(4):318.

PMID:
21283107
[PubMed - indexed for MEDLINE]
8.

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.

Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, O'Brien M, Grossbard EB, Magilavy DB.

Arthritis Rheum. 2011 Feb;63(2):337-45. doi: 10.1002/art.30114.

PMID:
21279990
[PubMed - indexed for MEDLINE]
Free Article
9.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A.

J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021. Epub 2011 Jan 10.

PMID:
21220608
[PubMed - indexed for MEDLINE]
10.

Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.

Thoma G, Nuninger F, Falchetto R, Hermes E, Tavares GA, Vangrevelinghe E, Zerwes HG.

J Med Chem. 2011 Jan 13;54(1):284-8. doi: 10.1021/jm101157q. Epub 2010 Dec 14.

PMID:
21155605
[PubMed - indexed for MEDLINE]
11.

In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.

Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H, Nussenzveig R, Prchal JT, Bearss DJ, Parker CJ.

Exp Hematol. 2011 Jan;39(1):14-25. doi: 10.1016/j.exphem.2010.09.013. Epub 2010 Oct 8.

PMID:
20934482
[PubMed - indexed for MEDLINE]
12.

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB.

N Engl J Med. 2010 Sep 30;363(14):1303-12. doi: 10.1056/NEJMoa1000500. Epub 2010 Sep 22.

PMID:
20879879
[PubMed - indexed for MEDLINE]
Free Article
13.

Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.

Shayani S.

Ther Drug Monit. 2010 Dec;32(6):680-7. doi: 10.1097/FTD.0b013e3181f4d9c5. Review.

PMID:
20864900
[PubMed - indexed for MEDLINE]
14.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A.

N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.

PMID:
20843246
[PubMed - indexed for MEDLINE]
Free Article
15.

Deciphering the anticancer mechanisms of sunitinib.

Pal SK, Figlin RA, Yu H.

Cancer Biol Ther. 2010 Oct 1;10(7):712-4. doi: 10.4161/cbt.10.7.13130. Epub 2010 Oct 1. No abstract available.

PMID:
20716960
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment.

Steele AJ, Prentice AG, Cwynarski K, Hoffbrand AV, Hart SM, Lowdell MW, Samuel ER, Wickremasinghe RG.

Blood. 2010 Nov 25;116(22):4569-77. doi: 10.1182/blood-2009-09-245811. Epub 2010 Aug 17.

PMID:
20716767
[PubMed - indexed for MEDLINE]
Free Article
17.

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.

Dawson MA, Curry JE, Barber K, Beer PA, Graham B, Lyons JF, Richardson CJ, Scott MA, Smyth T, Squires MS, Thompson NT, Green AR, Wallis NG.

Br J Haematol. 2010 Jul;150(1):46-57. doi: 10.1111/j.1365-2141.2010.08175.x. Epub 2010 May 7.

PMID:
20507304
[PubMed - indexed for MEDLINE]
18.

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.

Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW.

Blood. 2010 Jun 24;115(25):5232-40. doi: 10.1182/blood-2009-05-223727. Epub 2010 Apr 12.

PMID:
20385788
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Genetic deficiency of Syk protects mice from autoantibody-induced arthritis.

Jakus Z, Simon E, Balázs B, Mócsai A.

Arthritis Rheum. 2010 Jul;62(7):1899-910. doi: 10.1002/art.27438.

PMID:
20201079
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.

Kim BH, Jee JG, Yin CH, Sandoval C, Jayabose S, Kitamura D, Bach EA, Baeg GH.

Mol Cancer. 2010 Feb 11;9:36. doi: 10.1186/1476-4598-9-36.

PMID:
20149240
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk